Table 5. Comparison of LasR Antagonist or Agonist Potency between Pump-Active (PAO-JP2) and Pump-Mutant (PAO-JG21) P. aeruginosa LasR Reporter Strainsa.
| antagonism | |||
|---|---|---|---|
| compoundb | PAO-JP2 IC50 (μM) | PAO-JG21 IC50 (μM) | fold changec |
| 2 (OOHL) | 5.5 | 0.57 | 9.6 |
| 3 (OHHL) | 40 | 41 | 1.0 |
| 5 | 73 | 8.9 | 8.2 |
| 6 | 175 | 20 | 8.8 |
| 7 | 116 | 8.2 | 14.1 |
| 8 | 12 | 1.5 | 8.0 |
| 9 | 3 | 0.42 | 7.1 |
| 10 (CL) | 21 | 1.3 | 16.2 |
| 12 | 9.7 | 3.7 | 2.6 |
| 18 (V-06-018) | 5.2 | 6.1 | 0.9 |
| 20 (TP-5) | 69 | 63 | 1.1 |
| 22 (PD-12) | 2.5 | 0.11 | 22.7 |
| agonism | |||
|---|---|---|---|
| compound | PAO-JP2 IC50 (μM) | PAO-JG21 IC50 (μM) | fold changeb |
| 1 (OdDHL) | 0.14 | 0.019 | 7.4 |
| 2 | >200 | 26 | >7.7 |
| 8 | >200 | 24 | >8.3 |
| 9 | 140 | 8.6 | 16.3 |
| 11 (ITC-12) | 2.6 | 1.3 | 2.0 |
| 14 | 17 | 15 | 1.1 |
| 16 (mBTL) | 4.2 | 0.56 | 7.5 |
| 19 (TP-1) | 0.071 | 0.036 | 2.0 |
a
Both strains utilize the plasmid plasI-LVAgfp to report compound ability to mediate LasR expression of lasI-LVAgfp.
b
Data for compounds with incalculable fold-changes in potency (due to incomplete dose–response curves) are listed in Table S4.
c
Compounds with statistically insignificant shifts in EC50 (p > 0.1) are shown in bold. For statistical analysis, see Table S4.